Key Facts The Absolute Risk Expansion: The calculated increase in absolute risk is remarkably small, manifesting as approximately 3 to 4 additional cases of ischemic optic neuropathy per 10,000 patients treated with GLP-1 receptor agonists over a standard 18-month therapeutic window
People will need to be obese or overweight and have at least one weight-related health condition to use GLP-1 medications
The Enervit E.SPORT Gel was built for exactly that moment
The Institute of Food Technologists (IFT) recently hosted a webinar to examine how expanding use of GLP-1 weight-loss medications is reshaping food consumption, nutrition priorities, and product innovation
Sermorelin's effects on sleep and energy may appear within 2 to 4 weeks, while body composition improvements generally become measurable over 3 to 6 months
While lifestyle changes like diet and exercise can help with high blood pressure, they arent always enough